CORRECTION

Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Anca D. Askanase · Enxu Zhao · Julie Zhu · Roman Bilyk ·
Richard A. Furie

Published online: August 30, 2021
© The Author(s) 2021

Correction to: Rheumatol Ther (2020) 7:893–908
<https://doi.org/10.1007/s40744-020-00236-1>

In the original article published, the data we received from our CRO laboratory inadvertently labelled cytokine Tumor Necrosis Factor Ligand 13B (also known as BAFF) as Tumor Necrosis Factor Ligand 13 (also known as APRIL). Therefore, we believed that the data we were reporting in our Figure 3 was for APRIL, when it was actually data for BAFF. Since APRIL and BAFF are members of the same family of proteins, can bind to the same receptors, and are both involved in B cell survival and proliferation, this oversight did not change the conclusions drawn in the manuscript of repository corticotropin injection being associated with B cell immunomodulation.

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s40744-020-00236-1>.

A. D. Askanase (✉)
Columbia University Medical Center, New York, NY,
USA
e-mail: ada20@cumc.columbia.edu

E. Zhao · J. Zhu · R. Bilyk
Mallinckrodt Pharmaceuticals, Bedminster, NJ, USA

R. A. Furie
Zucker School of Medicine at Hofstra/Northwell,
Hempstead, NY, USA

OPEN ACCESS

This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc/4.0/>.